Denali Therapeutics Inc. Common Stock (DNLI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Denali Therapeutics Inc. Common Stock (DNLI)
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Key Insights
Critical company metrics and information
Share Price
$25.10Market Cap
$3.61 BillionTotal Outstanding Shares
143.92 Million SharesTotal Employees
390Dividend
No dividendIPO Date
December 8, 2017SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.denalitherapeutics.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-57.38 Million |
| Net Cash Flow From Operating Activities | $-362.64 Million |
| Net Cash Flow From Financing Activities | $493.18 Million |
| Net Cash Flow From Investing Activities | $-187.92 Million |
| Net Cash Flow From Operating Activities, Continuing | $-362.64 Million |
| Net Cash Flow From Investing Activities, Continuing | $-187.92 Million |
| Net Cash Flow From Financing Activities, Continuing | $493.18 Million |
| Net Cash Flow, Continuing | $-57.38 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $14.54 Million |
| Net Income/Loss Attributable To Parent | $-427.49 Million |
| Net Income/Loss | $-427.49 Million |
| Operating Expenses | $504.60 Million |
| Income/Loss From Continuing Operations After Tax | $-427.49 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $-308.02 Million |
| Benefits Costs and Expenses | $322.56 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Diluted Average Shares | $162.88 Million |
| Research and Development | $404.46 Million |
| Other Operating Expenses | $100.15 Million |
| Operating Income/Loss | $-490.07 Million |
| Diluted Earnings Per Share | $-2.76 |
| Net Income/Loss Available To Common Stockholders, Basic | $-427.49 Million |
| Basic Average Shares | $328.87 Million |
| Basic Earnings Per Share | $-2.76 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Costs And Expenses | $504.60 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $50.82 Million |
| Accounts Payable | $9.59 Million |
| Liabilities | $135.52 Million |
| Noncurrent Liabilities | $48.42 Million |
| Other Non-current Assets | $534.35 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.32 Billion |
| Current Assets | $868.84 Million |
| Assets | $1.45 Billion |
| Equity | $1.32 Billion |
| Liabilities And Equity | $1.45 Billion |
| Noncurrent Assets | $585.17 Million |
| Current Liabilities | $87.09 Million |
| Wages | $14.87 Million |
| Other Current Liabilities | $62.63 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.